GO
Loading...

Enter multiple symbols separated by commas

Stocks Novartis AG

More

  • GENEVA— Swiss drug maker Novartis says it will cooperate with California- based biotech giant Amgen to develop and sell neuroscience treatments for illnesses and ailments like Alzheimer's disease and migraine headaches. A Novartis statement released late Tuesday said that as part of the deal, Amgen will make initial payments and cover some research and...

  • LONDON, Sept 1- Novartis and Amgen are joining forces in the hunt for an Alzheimer's treatment, in the latest sign that drugmakers believe an effective therapy for the memory-robbing disease may be within reach. Swiss-based Novartis said on Tuesday the alliance was part of a drive to build up its portfolio in neuroscience, following other deals this summer that...

  • NOVARTIS, AMGEN ALSO PLAN TO CO-DEVELOP AND CO-COMMERCIALISE AMGEN'S MIGRAINE PORTFOLIO.

  • NEW YORK— Canadian drugmaker Valeant will work with British competitor AstraZeneca on a potential treatment for psoriasis a few months after biotech giant Amgen said it was ending research on the drug because of a link to suicidal thoughts and behavior. Valeant could pay AstraZeneca as much as $445 million if the drug is successfully developed and approved...

  • Google, Sanofi team up to improve diabetes care Monday, 31 Aug 2015 | 10:26 AM ET

    Aug 31- Google Inc and French drugmaker Sanofi SA said they will partner to develop tools to improve the management and treatment of diabetes. Sanofi will work with Google's life sciences team to collect, analyze and understand information impacting diabetes, which is expected to affect 592 million by 2035, according to the International Diabetes...

  • FDA lays out proposal for naming lower-cost biotech drugs Thursday, 27 Aug 2015 | 10:33 AM ET

    But representatives for the generic drug industry warned that the FDA's proposal could curb those savings by making the drugs more difficult to prescribe. For decades, they have not faced generic competition because the FDA lacked a system to approve cheaper versions until 2012. Earlier this year the agency approved the first "biosimilar."

  • Getting a flu shot? There are new options Wednesday, 26 Aug 2015 | 4:07 PM ET

    TRENTON, N.J.— People planning on getting a flu shot this season have several options to discuss with their doctors. Three vaccines may appeal to people squeamish about the inch-long needles typically used to give flu shots. Another option gives a high dosage for those needing extra protection.

  • NEW YORK— Swiss drugmaker Novartis is buying a potential once-a-month multiple sclerosis drug from GlaxoSmithKline and could pay more than $1 billion in the latest deal between the two companies. Novartis currently sells the drug as a treatment for a type of leukemia, the result of a larger deal with GlaxoSmithKline. Novartis aims to start a late-stage...

  • Australia’s CSL warns of biotech bubble Monday, 10 Aug 2015 | 7:26 PM ET
    CSL employees.

    CSL has warned of a "biotech bubble" amid a frenzy of mergers and acquisition activity across the healthcare sector, the Financial Times reports.

  • Time to buy Germany Friday, 7 Aug 2015 | 2:05 PM ET
    The Brandenburg Gate in Berlin, Germany

    Time to buy Germany?

  • China gets tougher for Western drugmakers Thursday, 6 Aug 2015 | 7:42 AM ET

    *China now world's second biggest drugs market after U.S. *Novo Nordisk latest firm to suffer from China slowdown. Denmark's Novo Nordisk, the world's biggest insulin maker, was the latest to disappoint on Thursday with a 6 percent slide in Chinese sales.

  • Are we seeing a new dawn of innovation in pharma? Wednesday, 5 Aug 2015 | 1:50 AM ET
    Modernizing Medicine's electronic medical assistant.

    Innovation has always been the blood pumping through the body of the pharma industry, but in recent years the supply seemed to be getting poorer.

  • Aug 4- The U.S. Food and Drug Administration said it will update the label of Novartis AG's multiple sclerosis drug, Gilenya, after cases of serious brain infections were linked with its use. As a result, information about these cases is being added to the oral drug's label, the FDA said. The FDA had said in August 2013 that it was investigating a case of PML in a patient...

  • The U.S. Court of Appeals for the Federal Circuit also said five of Allergan's Lumigan patents were valid. The case stems from lawsuits Allergan filed in 2011 against Akorn's Hi-Tech Pharmacal Co Inc, Novartis AG, and Lupin Ltd over proposed generic versions of Lumigan, which has more than $600 million in annual sales. The Allergan patents cover an improved...

  • *Worldwide cancer drug spending $100 billion in 2014. LONDON, Aug 3- New cancer drug cocktails set to reach the market in the next few years will test the limits of premium pricing for life-saving medicines, forcing company executives to consider fresh market strategies. Pricey immunotherapies, offering long-lasting responses, are already starting to change...

  • Teva's MS drug Copaxone has strong second-quarter sales Thursday, 30 Jul 2015 | 8:42 AM ET

    JERUSALEM, July 30- Teva Pharmaceutical Industries, which this week revealed plans to buy Allergan's generics drugs business in a $40.5 billion deal, said on Thursday sales of its branded multiple sclerosis drug Copaxone rose 12 percent in the second quarter even though it faces new competition. Teva, the world's biggest generic drug maker, said that global...

  • GSK jumps 3% on strong EPS; Advair sales slump Wednesday, 29 Jul 2015 | 12:06 PM ET

    GlaxoSmithKline shares jumped 3 percent after the U.K.-listed pharmaceutical giant reported second-quarter earnings per share that were slightly higher than forecast on Wednesday.

  • GSK earnings relief Wednesday, 29 Jul 2015 | 10:00 AM ET
    GSK earnings relief

    Drugmaker GlaxoSmithKline beats street despite profit headwinds.

  • *HIV sales help offset margin slide post Novartis deal. LONDON, July 29- GlaxoSmithKline moved to reclaim its prowess as a research powerhouse on Wednesday by flagging up dozens of new drugs and vaccines in development, as demand for new HIV medicines helped it beat quarterly profit forecasts. The drugmaker recently sold its marketed cancer drugs to Novartis...

  • LONDON, July 29- British investor Neil Woodford is backing a start-up biopharmaceutical firm whose first venture will be to launch clinical trials of three drugs developed by Novartis. It said has raised $119 million from Woodford Investment and Invesco Perpetual among others, and has acquired drug programmes from Novartis for the treatment of brittle bone...